Login to Your Account

BioNumerik, Takeda Partnership Jeopardized By Tavocept Failure

By Karen Pihl-Carey

Wednesday, August 2, 2006
Privately held BioNumerik Pharmaceuticals Inc. learned that its lead neuropathy candidate failed to hit the primary endpoints in two Phase III studies, threatening the status of its North American partnership less than two months after the company withdrew an initial public offering. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription